Other Clinical Trial - Aim 3 Particle Swarm Optimization PIGD

Status Recruiting

Clinical Trial Summary

Clinical Trial Description

In Parkinson's disease (PD) patients undergoing standard-of-care Deep Brain Stimulation (DBS) therapy, to compare the effect on Parkinson's symptoms of two different neurostimulator settings designed to differ from each other as much as possible with respect to how much they activate two different neuroanatomical structures: the axonal pathway from Globus Pallidus (GP) to Pedunculopontine Nucleus (PPN), and the axonal pathway from PPN to GP. In this respect, the present protocol is similar to Protocol STUDY00008644. In fact, that protocol, and this one, cover different Aims of the same NIH-funded project. Protocol STUDY00008644 tested different neurostimulor settings for a few hours in the laboratory only; the present protocol also tests them for two weeks between laboratory testing sessions. This is essential, for several reasons. First, clinically relevant outcome measures, such as ADL (activities of dailly life) and QOL (quality of life) scales require observation for longer than a few hours in the laboratory. Second, DBS effects are not instantaneous, and prolonged observation is required to determine the full effect of neurostimulator settings. Third, we intend, if our hypothesis is confirmed (that activation of the PPN-to-GP pathway is most effective for the postural-instability / gait-disorder (PIGD) complex) to propose a clinical trial of neurostimulator settings designed to maximize activation of this pathway; the present protocol will yield data and experience essential for designing and proposing such a trial. ;

Study Design

Related Conditions & MeSH terms

Parkinson Disease
Parkinson's Disease and Parkinsonism
Parkinsonian Disorders

Clinical Trial Details

NCT number	NCT05934747
Study type	Interventional
Source	University of Minnesota
Contact	Scott Cooper, PhD, MD
Phone	612-626-9516
Email	secooper@umn.edu
Status	Recruiting
Phase	N/A
Start date	March 19, 2024
Completion date	June 30, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06037590` - A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops™ Relative to INBRIJA®	Phase 1
Enrolling by invitation	`NCT04799418` - STEM-PD Open Label Extension (OLE)	N/A
Not yet recruiting	`NCT06074393` - Caregiving in Advanced PD: A Tailored Support Group	N/A
Completed	`NCT05699161` - Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson	Phase 1/Phase 2
Not yet recruiting	`NCT05599659` - The Calgary Movement Disorders Advanced Care Pilot Program	N/A
Completed	`NCT04140708` - Effects of Exercise on Glymphatic Functioning and Neurobehavioral Correlates in Parkinson's Disease	N/A
Recruiting	`NCT03924414` - Trial of Parkinson's And Zoledronic Acid	Phase 4
Recruiting	`NCT06203106` - NYSCF Scientific Discovery Biobank
Not yet recruiting	`NCT06400017` - Mechanism and Application of DBS in the Treatment of PD	N/A
Recruiting	`NCT04797611` - STEM-Parkinson's Disease	N/A
Not yet recruiting	`NCT06174948` - The Use of the CUE1 in People With Parkinson's Disease and Related Disorders	N/A
Enrolling by invitation	`NCT04701177` - Digitally-enhanced, Decentralized, Multi-omics Observational Cohort
Recruiting	`NCT05962489` - Sleep-specific DBS Therapy in Parkinson's Disease	N/A
Recruiting	`NCT05931692` - Virtual Reality and Fear of Falling in Parkinson's Disease
Recruiting	`NCT04468919` - Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit	N/A
Completed	`NCT04925622` - Complex Eye Movements in Parkinson's Disease and Related Movement Disorders
Recruiting	`NCT04214509` - LIPAD - LRRK2 International Parkinson's Disease Study
Active, not recruiting	`NCT05677633` - Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease	Phase 1
Recruiting	`NCT06350617` - Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD Patients	N/A
Recruiting	`NCT06247423` - High-frequency Alternating Current Stimulation for Tremor in Parkinson's Disease.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.